Radial access may revolutionize the field of peripheral artery interventions

A new study published today in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) explores the safety and efficacy of using radial access (RA) for peripheral artery interventions. The study, conducted by a team of researchers from prominent medical centers, aimed at examining evaluating the safety and feasibility of RA for complex endovascular lower extremity interventions.

Peripheral artery interventions, such as angioplasty and stenting, are commonly performed to treat vascular conditions that obstruct blood flow to the lower extremities. Traditionally, these procedures have been performed using a femoral artery access approach. However, in recent years, there has been increasing interest in using radial access, which involves accessing the arteries of the wrist or forearm, as an alternative approach.

From June 2020 to June 2021, 120 patients at 8 U.S. centers were enrolled. Mean age was 68.7 years and 31.7% were women. The 224 lesions treated were in iliac (12.9%), femoro-popliteal (55.3%), isolated popliteal (11.9%) and tibial (19.5%) vessels. The primary efficacy endpoint was achieved in 112 (93.3%) patients. One patient (<1%) required femoral access conversion to complete the procedure. Thirty (25.0%) patients required one or more additional access to facilitate crossing and/or to complete the planned treatment (5 femoral, 10 tibial, and 17 pedal). No serious adverse events were adjudicated to the procedure. Mean procedure time and time-to-ambulation was 74 minutes and 3 hours 30 minutes; respectively, with 93.3% same day discharge. At 30 days, 97.2% of patients had ultrasound-confirmed RA patency.

The findings of the study demonstrated that radial access for peripheral artery interventions was associated with favorable safety profiles. Notably, the incidence of access site complications and major adverse cardiovascular events was significantly lower compared to the traditional femoral access approach. The results also showed comparable procedural success rates and long-term clinical outcomes between the two approaches.

Additionally, radial access was found to have the potential to be a safe and effective alternative for performing peripheral artery interventions. The researchers believe that the wrist and forearm offer several advantages over the traditional femoral access site, including improved patient comfort, reduced bleeding complications, and faster ambulation. Further research and clinical trials are warranted to validate these findings and establish radial access as a mainstream approach in this field.

This study contributes to the growing body of evidence supporting the use of radial access for peripheral artery interventions. As medical professionals continue to explore different approaches, advances in technology and techniques are expected to further enhance the safety and efficacy of these procedures. With its potential to improve patient outcomes and satisfaction, radial access may revolutionize the field of peripheral artery interventions."

Mehdi Shishehbor, DO, MPH, PhD, president of University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH, and lead author of the study

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Key reason why some cancers do not respond to immunotherapy identified